Abstract:Currently, amino-terminal PEGylated human granulocyte colony stimulating factor (huG-CSF) is used to prevent and treat neutropenia. Although huG-CSF has been used as a drug for more than 20 years, it has three significant drawbacks: (i) it relies on PEG aldehyde for PEGylation of the alpha-amino group of the first amino acid, and this leads to non-specific PEGylation of the epsilon amino group of lysine residues within the G-CSF; (ii) longer-acting G-CSF variants are desirable to reduce the risk of chemotherapy-associated neutropenia; and (iii) G-CSF cannot be administered on the day of chemotherapy. In an attempt to overcome the above drawbacks, we engineered cysteine variants of G-CSF to facilitate the maleimide PEG-based site-specific PEGylation that leads to a highly homogenous PEGylated product. Importantly, we have demonstrated that 20 kDa thiol-reactive PEG conjugated by maleimide chemistry to the Cys2 G-CSF variant exhibits leukocyte proliferative activity similar to that of the commercially available G-CSF conjugated with aldehyde PEG in a neutropenia mice model. Moreover, we have demonstrated that PEGylation of the cysteine variant of huG-CSF with higher molecular weight PEGs, such as 30 kDa PEG and 40 kDa PEG, leads to significantly prolonged leukocyte proliferation activity compared to the variant conjugated with 20 kDa PEG. Importantly, even a half-dose of the engineered variant conjugated with 40 kDa PEG exhibited significantly longer biological activity than the commercially available 20 kDa PEGylated huG-CSF. Finally, we have demonstrated that administration of the engineered variant conjugated with 40 kDa PEG on the day of administration of cyclophosphamide for inducing neutropenia in mice can alleviate neutropenia through leukocyte proliferation. In summary, this study provides the design of site-specific PEGylated huG-CSF variants with improved therapeutic potential. It opens the possibility of long-acting and same-day prophylactic administration of G-CSF after chemotherapy drug regimens. These results may pave the way for the development of potential G-CSF derivatives possessing longer half-lives and favorable clinical attributes.

Chemical Modification of Activated Polyethylene Glycol to Lysozyme and Granulocyte Colony-Stimulating Factor

Determination of the Modification Extent of PEG-rhG-CSF using Two-phase System

Study on rhG-CSF modified with polyethylene glycol]

Study on Polyethylene Glycol Modified Superoxide Dismutase

Studies on the Modification of Trypsin with Polyethylene Glycol Derivatives

Site-Directed Chemical Modification of Recombinant Human Afgf Mutant with Polyethylene Glycol

Modification of antimicrobial peptide with low molar mass poly(ethylene glycol).

Research on PEG Modification of Uricase

Discarded free PEG-based assay for obtaining the modification extent of pegylated proteins

Surface Modification of Ultrahigh Molecular Weight Polyethylene by the Poly(Ethylene Glycol)-Grafted Method and Its Effect on the Adsorption of Proteins and the Adhesion of Blood Platelets

Site-Directed Modification of Genetically Engineered Proteus Sp Lipase K107 Variants with A Polyethylene Glycol Derivative

Influence of Polyethyleneglycol Modification on Phagocytic Uptake of Polymeric Nanoparticles Mediated by Immunoglobulin G and Complement Activation.

Engineering a Pharmacologically Superior Form of Granulocyte-Colony-stimulating Factor by Fusion with Gelatin-Like-protein Polymer.

PEG Modification of Protein Drug

[Chemical modification of chymopapain with monomethoxypolyethylene glycol and its effect on enzymic activity and antigenicity].

Effect of PEGylation on Properties of Uricase

Methods of Polyethylene Glycol（PEG）activation and Analysis Methods for Polyethylene glycolated Protein

Effects of Modification of Amino Groups with Poly(Ethylene Glycol) on a Recombinant Uricase Frombacillusfastidiosus

Development of Site-Specific PEGylated Granulocyte Colony Stimulating Factor With Prolonged Biological Activity

Influence of PEG Chain on the Complement Activation Suppression and Longevity in Vivo Prolongation of the PCL Biomedical Nanoparticles

Influence of Different PEG Contents on the Phagocytic Uptake and Plasma Protein Adsorption of Mpeg-Plga-mpeg Nanoparticles